Boehringer Ingelheim CEO: «Pharma Doesn’t Need Rare Earths, Pharma Needs Bright Minds»

Shashank Deshpande, CEO of Boehringer Ingelheim, expresses concern about the state of pharmaceutical research in Germany. He criticizes that the approval processes for new medications in the country take too long compared to international standards.